Tumoral CD10 expression correlates with aggressive histology and prognosis in patients with malignant pleural mesothelioma Journal Article
| Authors: | Kadota, K.; Villena-Vargas, J.; Nitadori, J. I.; Sima, C. S.; Jones, D. R.; Travis, W. D.; Adusumilli, P. S. |
| Article Title: | Tumoral CD10 expression correlates with aggressive histology and prognosis in patients with malignant pleural mesothelioma |
| Abstract: | Background: Currently, tumor-node-metastasis stage and histologic type are the established prognostic factors for malignant pleural mesothelioma, whereas no prognostic markers have been established for clinical practice. We investigated the prognostic value of CD10, a metalloproteinase that can promote cancer aggressiveness through enzymatic degradation and intracellular signaling crosstalk, in malignant pleural mesothelioma. Methods: CD10 immunostaining was performed for 176 cases of malignant pleural mesothelioma (epithelioid, 148; biphasic, 14; sarcomatoid, 14), and its expression was dichotomized as negative (no staining) or positive (any staining). Epithelioid tumors were classified as pleomorphic subtype when cytologic pleomorphism was ≥10 % of the tumor. Overall survival (OS) was analyzed by log-rank tests and Cox proportional hazard models. Results: Tumoral CD10 expression was identified in 42 % of epithelioid non-pleomorphic tumors, 57 % of epithelioid pleomorphic tumors, 79 % of biphasic tumors, and 93 % of sarcomatoid tumors (p < 0.001). Positive CD10 expression was correlated with higher mitotic count (p = 0.002). Overall survival for patients with positive CD10 expression was significantly shorter than that for patients with negative CD10 expression in all patients (p = 0.001) and in patients with epithelioid tumor (p = 0.04). On multivariate analysis, CD10 expression was an independent prognostic factor for all patients (hazard ratio 1.48; p = 0.019). Conclusions: Tumoral CD10 expression correlated with aggressive histologic types and higher mitotic activity and is an independent prognostic factor for patients with malignant pleural mesothelioma. © 2015, Society of Surgical Oncology. |
| Keywords: | immunohistochemistry; adult; cancer survival; controlled study; human tissue; protein expression; aged; cancer surgery; major clinical study; overall survival; histopathology; cancer patient; lung resection; pleura mesothelioma; mitosis rate; pleurectomy; tumor classification; cytopathology; predictive value; intracellular signaling; aggressiveness; cancer prognosis; enzymatic degradation; human; male; female; article; membrane metalloendopeptidase |
| Journal Title: | Annals of Surgical Oncology |
| Volume: | 22 |
| Issue: | 9 |
| ISSN: | 1068-9265 |
| Publisher: | Springer |
| Date Published: | 2015-09-01 |
| Start Page: | 3136 |
| End Page: | 3143 |
| Language: | English |
| DOI: | 10.1245/s10434-015-4374-x |
| PROVIDER: | scopus |
| PMCID: | PMC4511716 |
| PUBMED: | 25608772 |
| DOI/URL: | |
| Notes: | Export Date: 2 September 2015 -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
Related MSK Work